These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 16144930)

  • 1. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
    Zhang X; Chen ZG; Choe MS; Lin Y; Sun SY; Wieand HS; Shin HJ; Chen A; Khuri FR; Shin DM
    Clin Cancer Res; 2005 Sep; 11(17):6261-9. PubMed ID: 16144930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
    Chen Z; Zhang X; Li M; Wang Z; Wieand HS; Grandis JR; Shin DM
    Clin Cancer Res; 2004 Sep; 10(17):5930-9. PubMed ID: 15355926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways.
    Lippman SM; Gibson N; Subbaramaiah K; Dannenberg AJ
    Clin Cancer Res; 2005 Sep; 11(17):6097-9. PubMed ID: 16144906
    [No Abstract]   [Full Text] [Related]  

  • 5. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
    Choe MS; Chen Z; Klass CM; Zhang X; Shin DM
    Clin Cancer Res; 2007 May; 13(10):3015-23. PubMed ID: 17505004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
    Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
    Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
    Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
    Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
    Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A
    J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
    Spinella F; Rosanò L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
    Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
    Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iressa (ZD 1839) inhibits phosphorylation of three different downstream signal transducers in head and neck cancer (SCCHN).
    Hambek M; Baghi M; Baumaun H; Strebhardt K; Adunka O; Gstöttner W; Knecht R
    Anticancer Res; 2005; 25(3B):1871-5. PubMed ID: 16158919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells.
    Matheny KE; Barbieri CE; Sniezek JC; Arteaga CL; Pietenpol JA
    Laryngoscope; 2003 Jun; 113(6):936-9. PubMed ID: 12782800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
    Huang SM; Harari PM
    Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
    Shin DM; Zhang H; Saba NF; Chen AY; Nannapaneni S; Amin AR; Müller S; Lewis M; Sica G; Kono S; Brandes JC; Grist WJ; Moreno-Williams R; Beitler JJ; Thomas SM; Chen Z; Shin HJ; Grandis JR; Khuri FR; Chen ZG
    Clin Cancer Res; 2013 Mar; 19(5):1244-56. PubMed ID: 23422093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
    Liu W; Chen Y; Wang W; Keng P; Finkelstein J; Hu D; Liang L; Guo M; Fenton B; Okunieff P; Ding I
    Am J Clin Oncol; 2003 Aug; 26(4):S103-9. PubMed ID: 12902866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas.
    Wu R; Abramson AL; Shikowitz MJ; Dannenberg AJ; Steinberg BM
    Clin Cancer Res; 2005 Sep; 11(17):6155-61. PubMed ID: 16144915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAT 3 activation in head and neck squamous cell carcinomas is controlled by the EGFR.
    Hambek M; Baghi M; Strebhardt K; May A; Adunka O; Gstöttner W; Knecht R
    Anticancer Res; 2004; 24(6):3881-6. PubMed ID: 15736426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
    Huang SM; Li J; Armstrong EA; Harari PM
    Cancer Res; 2002 Aug; 62(15):4300-6. PubMed ID: 12154033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.